HRP20051006A2 - Substituted spirobenzazepines - Google Patents

Substituted spirobenzazepines Download PDF

Info

Publication number
HRP20051006A2
HRP20051006A2 HR20051006A HRP20051006A HRP20051006A2 HR P20051006 A2 HRP20051006 A2 HR P20051006A2 HR 20051006 A HR20051006 A HR 20051006A HR P20051006 A HRP20051006 A HR P20051006A HR P20051006 A2 HRP20051006 A2 HR P20051006A2
Authority
HR
Croatia
Prior art keywords
chloro
compound
spiro
benzoundec
aza
Prior art date
Application number
HR20051006A
Other languages
English (en)
Croatian (hr)
Inventor
Patel Mona
J. Philip
Min
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of HRP20051006A2 publication Critical patent/HRP20051006A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20051006A 2003-06-17 2004-06-16 Substituted spirobenzazepines HRP20051006A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47937803P 2003-06-17 2003-06-17
PCT/US2004/019460 WO2005037795A2 (en) 2003-06-17 2004-06-16 Substituted spirobenzazepines

Publications (1)

Publication Number Publication Date
HRP20051006A2 true HRP20051006A2 (en) 2006-05-31

Family

ID=34465052

Family Applications (2)

Application Number Title Priority Date Filing Date
HR20051006A HRP20051006A2 (en) 2003-06-17 2004-06-16 Substituted spirobenzazepines
HR20090606T HRP20090606T1 (hr) 2003-06-17 2004-06-16 Supstituirani spirobenzazepini

Family Applications After (1)

Application Number Title Priority Date Filing Date
HR20090606T HRP20090606T1 (hr) 2003-06-17 2004-06-16 Supstituirani spirobenzazepini

Country Status (30)

Country Link
US (2) US20040266752A1 (enExample)
EP (1) EP1633719B1 (enExample)
JP (1) JP5252614B2 (enExample)
KR (1) KR101086246B1 (enExample)
CN (1) CN100467454C (enExample)
AR (1) AR044782A1 (enExample)
AT (1) ATE444953T1 (enExample)
AU (1) AU2004281257C1 (enExample)
BR (1) BRPI0411598A (enExample)
CA (1) CA2529649C (enExample)
CL (1) CL2004001507A1 (enExample)
CR (1) CR8168A (enExample)
CY (1) CY1109585T1 (enExample)
DE (1) DE602004023501D1 (enExample)
DK (1) DK1633719T3 (enExample)
EA (1) EA011089B1 (enExample)
ES (1) ES2332724T3 (enExample)
HR (2) HRP20051006A2 (enExample)
IL (1) IL172630A (enExample)
ME (1) ME00320B (enExample)
NO (1) NO20060247L (enExample)
NZ (1) NZ544180A (enExample)
PL (1) PL1633719T3 (enExample)
PT (1) PT1633719E (enExample)
RS (1) RS20050930A (enExample)
SI (1) SI1633719T1 (enExample)
TW (1) TWI354555B (enExample)
UA (1) UA82236C2 (enExample)
WO (1) WO2005037795A2 (enExample)
ZA (1) ZA200600430B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007516177A (ja) * 2003-06-17 2007-06-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 非ペプチド置換スピロベンゾアゼピン誘導体の製造方法
EP1984342A2 (en) * 2006-01-20 2008-10-29 Janssen Pharmaceutica, N.V. Novel solid forms of (4r)-1-[4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl]-1,2,3,5-tetrahydro-spiro[4h-1-benzazepine-4,1'-[2]cyclopentene]-3'-carboxylic acid
JP2010504352A (ja) * 2006-09-22 2010-02-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ バソプレッシン拮抗薬としてのスピロベンズアゼピン類
ATE532786T1 (de) * 2006-09-22 2011-11-15 Janssen Pharmaceutica Nv Spirobenzazepine als vasopressinantagonisten
AR066834A1 (es) * 2007-06-06 2009-09-16 Janssen Pharmaceutica Nv Espirobenzoazepanos como antagonistas de vasopresina, composiciones farmaceuticas que los contienen, proceso de preparacion y usos para el tratamiento de afecciones cardiacas, renales y del sistema nervioso central.
WO2009061786A2 (en) * 2007-11-07 2009-05-14 Janssen Pharmaceutica N.V. Combination therapy comprising angiotensin converting enzyme inhibitors and vasopressin receptor antagonists
WO2014062888A1 (en) 2012-10-18 2014-04-24 University Of South Florida Compositions and methods for treating stroke
RU2642783C2 (ru) 2012-12-26 2018-01-26 Санва Кагаку Кенкюсо Ко., Лтд. Новое производное бензоазепина и его медицинское применение
US20240190884A1 (en) * 2021-03-05 2024-06-13 Shanghai Jemincare Pharmaceutical Co., Ltd New-type benzazepine fused ring derivative

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617302A (en) * 1984-10-15 1986-10-14 Eli Lilly And Company Inotropic agents
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
DE69026708T2 (de) 1989-10-20 1997-04-03 Otsuka Pharma Co Ltd Benzoheterozyklische verbindungen
US5985869A (en) * 1989-10-20 1999-11-16 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5849780A (en) * 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5663431A (en) * 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2708605A1 (fr) * 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
EP0663827A4 (en) * 1992-10-07 1995-11-15 Merck & Co Inc TOKOLYTIC OXYTOCINE RECEPTOR ANTAGONISTS.
US5512563A (en) * 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
ES2143049T3 (es) * 1994-04-22 2000-05-01 Pentech Pharmaceuticals Inc Formas sublinguales de dosificacion que contienen apomorfina y su uso para el tratamiento de la disfuncion erectil.
US5753648A (en) * 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
JP3282494B2 (ja) * 1995-05-16 2002-05-13 富士ゼロックス株式会社 画像定着装置
US5753715A (en) * 1995-06-02 1998-05-19 Ortho Pharmaceutical Corporation 2-disubstituted cyclohexenyl and cyclohexyl antimicrobial agents
US5726723A (en) * 1996-01-31 1998-03-10 Technology Research International Corporation Sub-twisted nematic liquid crystal display
AUPP150098A0 (en) 1998-01-27 1998-02-19 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
ES2250432T3 (es) * 2000-07-05 2006-04-16 Ortho-Mcneil Pharmaceutical, Inc. Espirobenzoazepinas no peptidicas sustituidas, antagonistas de la vasopresina.
JP2007516177A (ja) * 2003-06-17 2007-06-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 非ペプチド置換スピロベンゾアゼピン誘導体の製造方法

Also Published As

Publication number Publication date
AR044782A1 (es) 2005-10-05
AU2004281257C1 (en) 2010-07-01
MEP49108A (en) 2011-02-10
EP1633719A2 (en) 2006-03-15
SI1633719T1 (sl) 2010-01-29
CR8168A (es) 2008-09-10
KR101086246B1 (ko) 2011-11-23
CN100467454C (zh) 2009-03-11
CL2004001507A1 (es) 2005-05-27
EA011089B1 (ru) 2008-12-30
KR20060023157A (ko) 2006-03-13
HRP20090606T1 (hr) 2010-01-31
CA2529649A1 (en) 2005-04-28
PL1633719T3 (pl) 2010-03-31
IL172630A0 (en) 2006-04-10
BRPI0411598A (pt) 2006-08-29
DK1633719T3 (da) 2010-01-04
US20040266752A1 (en) 2004-12-30
ATE444953T1 (de) 2009-10-15
US20070179128A1 (en) 2007-08-02
AU2004281257A1 (en) 2005-04-28
WO2005037795A3 (en) 2005-07-28
JP2007521272A (ja) 2007-08-02
RS20050930A (sr) 2008-04-04
CA2529649C (en) 2012-01-31
ES2332724T3 (es) 2010-02-11
NO20060247L (no) 2006-03-13
DE602004023501D1 (de) 2009-11-19
EP1633719B1 (en) 2009-10-07
JP5252614B2 (ja) 2013-07-31
CY1109585T1 (el) 2014-08-13
ZA200600430B (en) 2009-08-26
US7687494B2 (en) 2010-03-30
PT1633719E (pt) 2009-11-11
ME00320B (me) 2011-05-10
AU2004281257B2 (en) 2010-02-04
WO2005037795A2 (en) 2005-04-28
IL172630A (en) 2011-10-31
EA200501831A1 (ru) 2006-06-30
CN1835925A (zh) 2006-09-20
UA82236C2 (en) 2008-03-25
NZ544180A (en) 2009-01-31
TWI354555B (en) 2011-12-21
TW200515911A (en) 2005-05-16

Similar Documents

Publication Publication Date Title
US7687494B2 (en) Substituted spirobenzazepines
AU716122B2 (en) Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders
US7825111B2 (en) Substituted spiroheterocycles
DE60208068T2 (de) Benzamidinderivate als antagonisten von orexinrezeptoren
ES2224604T3 (es) Bococñp(2.2. 1)heptanos y compuestos relacionados.
RU2197493C2 (ru) Производные 5h-тиазол[3,2-а]пиримидина, промежуточные продукты и лекарственное средство
JP2010500372A (ja) オピオイド受容体に対するアンタゴニストまたはインバースアゴニストとしての新規化合物
ES2374582T3 (es) Espirobenzazepinas usadas como antagonistas de vasopresina.
JP6518789B2 (ja) 精神障害の処置において使用するためのテトラゾール誘導体
EP3596080B1 (en) Pharmacologically active alicyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives
TW200812976A (en) Compounds which inhibit the glycine transporter and uses thereof
CN116075514A (zh) 药理学活性的杂环取代的吡唑并[1,5-a]嘧啶衍生物
JP5947907B2 (ja) Ｋｃｎｑカリウムチャネル作動薬として使用できる新規な化合物、その製造方法および用途
CA2071092A1 (en) 1,4-benzodiazepines with 5-membered heterocyclic rings
TW200846328A (en) GlyT1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
MXPA05014057A (en) Substituted spirobenzazepines
JP3727791B2 (ja) 二環式［３．１．０］ヘキサン及び関連化合物
CN100551915C (zh) 8-氯-2,3-苯二氮䓬衍生物
EP3369736A1 (en) Morphinan derivative and medical usage thereof

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20130506

Year of fee payment: 10

OBST Application withdrawn